Zim Laboratories Limited (ZIMLAB) - Net Assets
Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has net assets worth Rs2.51 Billion INR (≈ $27.18 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.70 Billion ≈ $50.84 Million USD) and total liabilities (Rs2.19 Billion ≈ $23.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ZIMLAB tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.51 Billion |
| % of Total Assets | 53.46% |
| Annual Growth Rate | 7.42% |
| 5-Year Change | 56.91% |
| 10-Year Change | 156.5% |
| Growth Volatility | 9.85 |
Zim Laboratories Limited - Net Assets Trend (2013–2025)
This chart illustrates how Zim Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See ZIMLAB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zim Laboratories Limited (2013–2025)
The table below shows the annual net assets of Zim Laboratories Limited from 2013 to 2025. For live valuation and market cap data, see Zim Laboratories Limited market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.52 Billion ≈ $27.28 Million |
+5.65% |
| 2024-03-31 | Rs2.39 Billion ≈ $25.82 Million |
+19.17% |
| 2023-03-31 | Rs2.00 Billion ≈ $21.67 Million |
+14.02% |
| 2022-03-31 | Rs1.76 Billion ≈ $19.00 Million |
+9.31% |
| 2021-03-31 | Rs1.61 Billion ≈ $17.38 Million |
+4.50% |
| 2020-03-31 | Rs1.54 Billion ≈ $16.64 Million |
+1.79% |
| 2019-03-31 | Rs1.51 Billion ≈ $16.34 Million |
+10.63% |
| 2018-03-31 | Rs1.37 Billion ≈ $14.77 Million |
+15.44% |
| 2017-03-31 | Rs1.18 Billion ≈ $12.80 Million |
+20.33% |
| 2016-03-31 | Rs983.37 Million ≈ $10.63 Million |
+4.38% |
| 2015-03-31 | Rs942.10 Million ≈ $10.19 Million |
-18.80% |
| 2014-03-31 | Rs1.16 Billion ≈ $12.55 Million |
+8.62% |
| 2013-03-31 | Rs1.07 Billion ≈ $11.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zim Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 232.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.69 Billion | 67.02% |
| Common Stock | Rs487.26 Million | 19.32% |
| Other Comprehensive Income | Rs264.24 Million | 10.48% |
| Other Components | Rs80.30 Million | 3.18% |
| Total Equity | Rs2.52 Billion | 100.00% |
Zim Laboratories Limited Competitors by Market Cap
The table below lists competitors of Zim Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ittifak Holding A.S.
IS:LRSHO
|
$60.08 Million |
|
Samsung Climat
KO:006660
|
$60.09 Million |
|
LiveOne Inc
NASDAQ:LVO
|
$60.09 Million |
|
Bound and Beyond PCL
BK:BEYOND-R
|
$60.12 Million |
|
Genie Music Corporation
KQ:043610
|
$60.06 Million |
|
PTL Enterprises Limited
NSE:PTL
|
$60.06 Million |
|
Quantum X Labs Inc.
NASDAQ:QXL
|
$60.01 Million |
|
Safety Shot Inc
NASDAQ:SHOT
|
$60.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zim Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,387,458,000 to 2,522,375,000, a change of 134,917,000 (5.7%).
- Net income of 121,652,000 contributed positively to equity growth.
- Dividend payments of 569,000 reduced retained earnings.
- Other comprehensive income increased equity by 29,266,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs121.65 Million | +4.82% |
| Dividends Paid | Rs569.00K | -0.02% |
| Other Comprehensive Income | Rs29.27 Million | +1.16% |
| Other Changes | Rs-15.43 Million | -0.61% |
| Total Change | Rs- | 5.65% |
Book Value vs Market Value Analysis
This analysis compares Zim Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.41x to 2.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | Rs25.83 | Rs113.97 | x |
| 2014-03-31 | Rs24.18 | Rs113.97 | x |
| 2015-03-31 | Rs19.37 | Rs113.97 | x |
| 2016-03-31 | Rs20.22 | Rs113.97 | x |
| 2017-03-31 | Rs24.33 | Rs113.97 | x |
| 2018-03-31 | Rs28.08 | Rs113.97 | x |
| 2019-03-31 | Rs31.03 | Rs113.97 | x |
| 2020-03-31 | Rs31.59 | Rs113.97 | x |
| 2021-03-31 | Rs33.02 | Rs113.97 | x |
| 2022-03-31 | Rs36.06 | Rs113.97 | x |
| 2023-03-31 | Rs41.12 | Rs113.97 | x |
| 2024-03-31 | Rs49.00 | Rs113.97 | x |
| 2025-03-31 | Rs51.84 | Rs113.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zim Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.25%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 1.87x
- Recent ROE (4.82%) is below the historical average (6.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 8.92% | 5.15% | 0.85x | 2.04x | Rs-11.57 Million |
| 2014 | 8.74% | 4.47% | 0.86x | 2.27x | Rs-14.62 Million |
| 2015 | -22.94% | -8.25% | 0.99x | 2.81x | Rs-310.29 Million |
| 2016 | 5.18% | 1.93% | 1.03x | 2.60x | Rs-47.36 Million |
| 2017 | 15.71% | 8.10% | 0.89x | 2.19x | Rs67.53 Million |
| 2018 | 13.99% | 7.19% | 0.89x | 2.18x | Rs54.50 Million |
| 2019 | 10.15% | 4.70% | 0.99x | 2.17x | Rs2.30 Million |
| 2020 | 2.14% | 1.26% | 0.80x | 2.11x | Rs-120.86 Million |
| 2021 | 4.55% | 2.38% | 0.95x | 2.02x | Rs-87.58 Million |
| 2022 | 8.28% | 4.40% | 0.97x | 1.94x | Rs-30.21 Million |
| 2023 | 12.20% | 6.13% | 1.17x | 1.70x | Rs44.00 Million |
| 2024 | 7.22% | 4.69% | 0.82x | 1.87x | Rs-66.28 Million |
| 2025 | 4.82% | 3.25% | 0.79x | 1.87x | Rs-130.59 Million |
Industry Comparison
This section compares Zim Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,118,163,484
- Average return on equity (ROE) among peers: 13.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zim Laboratories Limited (ZIMLAB) | Rs2.51 Billion | 8.92% | 0.87x | $60.07 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $25.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.36 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $645.54 Million |
| Abbott India Limited (ABBOTINDIA) | $2.31 Billion | 29.62% | 0.43x | $6.01 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $32.64 Billion | 21.83% | 0.24x | $4.15 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $996.26 Million |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.62 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $22.20 Billion | 18.58% | 0.77x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $268.52 Billion | 7.18% | 0.49x | $8.98 Billion |
About Zim Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more